Home  »  Hot Stocks   »  VYNE Therapeutics Inc. (VYNE) Reveals an Earnings ...

VYNE Therapeutics Inc. (VYNE) Reveals an Earnings Mystery

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

VYNE Therapeutics Inc. (NASDAQ:VYNE) went down by -4.57% from its latest closing price compared to the recent 1-year high of $13.20. The company’s stock price has collected -3.85% of loss in the last five trading sessions. Press Release reported 2 hours ago that Thinking about buying stock in Adagio Therapeutics, Vyne Therapeutics, PetVivo, BTCS Inc, or Mattel?

Is It Worth Investing in VYNE Therapeutics Inc. (NASDAQ :VYNE) Right Now?

Plus, the 36-month beta value for VYNE is at 0.72. Opinions of the stock are interesting as 5 analysts out of 5 who provided ratings for VYNE Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


The average price from analysts is $6.25, which is $4.85 above the current price. VYNE currently public float of 49.57M and currently shorts hold a 4.20% ratio of that float. Today, the average trading volume of VYNE was 2.47M shares.

VYNE’s Market Performance

VYNE stocks went down by -3.85% for the week, with a monthly drop of -18.03% and a quarterly performance of -23.08%, while its annual performance rate touched -84.66%. The volatility ratio for the week stands at 5.46% while the volatility levels for the past 30 days are set at 8.50% for VYNE Therapeutics Inc.. The simple moving average for the period of the last 20 days is -10.81% for VYNE stocks with a simple moving average of -62.32% for the last 200 days.

Analysts’ Opinion of VYNE

Many brokerage firms have already submitted their reports for VYNE stocks, with H.C. Wainwright repeating the rating for VYNE by listing it as a “Buy.” The predicted price for VYNE in the upcoming period, according to H.C. Wainwright is $7 based on the research report published on December 06th of the previous year 2021.

VYNE Trading at -16.73% from the 50-Day Moving Average

After a stumble in the market that brought VYNE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.77% of loss for the given period.

Volatility was left at 8.50%, however, over the last 30 days, the volatility rate increased by 5.46%, as shares sank -7.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.18% lower at present.

During the last 5 trading sessions, VYNE rose by +3.43%, which changed the moving average for the period of 200-days by -84.59% in comparison to the 20-day moving average, which settled at $1.0658. In addition, VYNE Therapeutics Inc. saw -1.96% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at VYNE starting from LEPORE PATRICK G, who purchase 12,500 shares at the price of $1.02 back on Nov 30. After this action, LEPORE PATRICK G now owns 62,500 shares of VYNE Therapeutics Inc., valued at $12,699 using the latest closing price.

LEPORE PATRICK G, the Director of VYNE Therapeutics Inc., purchase 12,500 shares at $1.60 during a trade that took place back on Aug 25, which means that LEPORE PATRICK G is holding 50,000 shares at $20,000 based on the most recent closing price.

Stock Fundamentals for VYNE

Current profitability levels for the company are sitting at:

  • -448.13 for the present operating margin
  • +93.37 for the gross margin

The net margin for VYNE Therapeutics Inc. stands at -1217.40. The total capital return value is set at -132.98, while invested capital returns managed to touch -365.02. Equity return is now at value -128.60, with -74.10 for asset returns.

Based on VYNE Therapeutics Inc. (VYNE), the company’s capital structure generated 92.77 points at debt to equity in total, while total debt to capital is 48.13. Total debt to assets is 37.11, with long-term debt to equity ratio resting at 90.76. Finally, the long-term debt to capital ratio is 47.08.

>> 7 Top Picks for the Post-Pandemic Economy <<

When we switch over and look at the enterprise to sales, we see a ratio of 1.85, with the company’s debt to enterprise value settled at 0.19. The receivables turnover for the company is 2.65 and the total asset turnover is 0.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.07.

Leave a Comment

Your email address will not be published. Required fields are marked *

Is Teradyne Inc. (TER) a Keeper?

Teradyne Inc. (NASDAQ:TER) went up by 3.99% from its latest closing price compared to the recent 1-year high of $168.91. The company’s stock price has




Download Free eBook For


100% free. stop anytime no spam